Medullary thyroid cancer prevention: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Medullary thyroid cancer}} {{CMG}}; {{AE}} {{Ammu}} ==Overview== According to the American Society of Clinical Oncology, surveillance for medullary thyroid cancer...") |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
According to the American Society of Clinical Oncology, surveillance for medullary thyroid cancer by annual measurement of serum [[calcitonin]], serum [[calcium]], serum [[parathyroid hormone]], and catacholamines is recommended postsurgically to monitor for recurrence and complications for medullary thyroid cancer. | According to the American Society of Clinical Oncology, surveillance for medullary thyroid cancer by annual measurement of serum [[calcitonin]], serum [[calcium]], serum [[parathyroid hormone]], and catacholamines is recommended postsurgically to monitor for recurrence and complications for medullary thyroid cancer. | ||
== | ==Prevention== | ||
{| style="border: 2px solid #DCDCDC; font-size: 90%; width: 60%;" align=left | {| style="border: 2px solid #DCDCDC; font-size: 90%; width: 60%;" align=left | ||
! style="padding: 0 5px; font-size: 120%; background: #4479BA" align=left| ''{{fontcolor|#FFF| Surveillance of medullary thyroid cancer}}'' | ! style="padding: 0 5px; font-size: 120%; background: #4479BA" align=left| ''{{fontcolor|#FFF| Surveillance of medullary thyroid cancer}}'' | ||
| Line 11: | Line 11: | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''Recurrent or residual [[medullary thyroid cancer]] post [[thyroidectomy]] is detected by measurement of serum [[calcitonin]] annually''' | ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''Recurrent or residual [[medullary thyroid cancer]] post [[thyroidectomy]] is detected by measurement of serum [[calcitonin]] annually''' | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" colspan="2"|<small>Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/<ref>{{Cite journal| author = [[Jessica Marquard]] & [[Charis Eng]] | | style="padding: 5px 5px; background: #F5F5F5;" colspan="2"|<small>Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/<ref>{{Cite journal| author = [[Jessica Marquard]] & [[Charis Eng]] | ||
Revision as of 09:48, 16 November 2015
|
Medullary thyroid cancer Microchapters |
|
Differentiating Medullary thyroid cancer from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Medullary thyroid cancer prevention On the Web |
|
American Roentgen Ray Society Images of Medullary thyroid cancer prevention |
|
Risk calculators and risk factors for Medullary thyroid cancer prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the American Society of Clinical Oncology, surveillance for medullary thyroid cancer by annual measurement of serum calcitonin, serum calcium, serum parathyroid hormone, and catacholamines is recommended postsurgically to monitor for recurrence and complications for medullary thyroid cancer.
Prevention
| Surveillance of medullary thyroid cancer | |
|---|---|
| Serum calcium level annually for people diagnosed with multiple endocrine neoplasia type 2A | |
| Recurrent or residual medullary thyroid cancer post thyroidectomy is detected by measurement of serum calcitonin annually | |
| Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/[1] | |
References
- ↑ Jessica Marquard & Charis Eng (1993). "Multiple Endocrine Neoplasia Type 2". PMID 020301434.